Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells

Mattias Carlsten, Håkan Norell, Yenan T. Bryceson, Isabel Poschke, Kjell Schedvins, Hans-Gustaf Ljunggren, Rolf Kiessling and Karl-Johan Malmberg

J Immunol 2009; 183:4921-4930; doi: 10.4049/jimmunol.0901226
http://www.jimmunol.org/content/183/8/4921

Supplementary Material http://www.jimmunol.org/content/suppl/2009/09/29/183.8.4921.DC1

References This article cites 61 articles, 33 of which you can access for free at: http://www.jimmunol.org/content/183/8/4921.full#ref-list-1

Why The JI? Submit online.
- Rapid Reviews! 30 days* from submission to initial decision
- No Triage! Every submission reviewed by practicing scientists
- Fast Publication! 4 weeks from acceptance to publication

*average

Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription

Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html

Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts
Primary Human Tumor Cells Expressing CD155 Impair Tumor Targeting by Down-Regulating DNAM-1 on NK Cells

Mattias Carlsten, Håkan Norell, Yenan T. Bryceson, Isabel Poschke, Kjell Schedvins, Hans-Gustaf Ljunggren, Rolf Kiessling, and Karl-Johan Malmberg

The activating NK cell receptor DNAX accessory molecule-1 (DNAM-1) contributes to tumor immune surveillance and plays a crucial role in NK cell-mediated recognition of several types of human tumors, including ovarian carcinoma. Relative to autologous peripheral blood NK cells, tumor-associated NK cells expressed reduced levels of the DNAM-1, CD24, and CD16 receptors and were hypo-responsive to HLA class I-deficient K562 cells and to coactivation via DNAM-1 and 2B4. Moreover, tumor-associated NK cells were also refractory to CD16 receptor stimulation, resulting in diminished Ab-dependent cellular cytotoxicity against autologous tumor cells. Coincubation of NK cells with ovarian carcinoma cells expressing the DNAM-1 ligand CD155 led to reduction of DNAM-1 expression. Therefore, NK cell-mediated rejection of ovarian carcinoma may be limited by perturbed DNAM-1 expression on tumor-associated NK cells induced by chronic ligand exposure. Thus, these data support the notion that tumor-induced alterations of activating NK cell receptor expression may hamper immune surveillance and promote tumor progression.

The Journal of Immunology, 2009, 183: 4921–4930.

Natural killer cells are lymphocytes of the innate immune system that recognize and kill tumor cells without prior sensitization (1). Human NK cells can be divided into two main functional subsets based on the intensity of CD56 expression (2). Although there is a degree of functional overlap, CD56dim NK cells have a potent cytotoxic function, whereas perforinlowCD56bright NK cells are thought to have immunoregulatory properties (2–5). Recent data support the notion that CD56bright and CD56dim NK cells represent different stages of maturation, with CD56dim NK cells being the more differentiated cell type (6).

NK cells are regulated by a balance of activating and inhibitory signals from cell surface receptors (7). The inhibitory signals are mediated mainly by HLA class I-binding receptors, including killer cell Ig-like receptors (KIRs), CD94/NKG2A, and leukocyte Ig-like receptor B1 (LILR-B1) (8). Activating signals are encoded by a wide array of receptors, including NKG2D, DNAX accessory molecule-1 (DNAM-1), natural cytotoxicity receptors (NKp30, NKp44, NKp46), CD94/NKG2C, and KIR with activating intra-cellular domains (7). Additionally, the low-affinity FcγRIIA receptor CD16 mediates Ab-dependent cellular cytotoxicity (ADCC). Costimulatory receptors and adhesion molecules such as 2B4 and LFA-1 are also involved in the regulation of NK cell activity (7). Engagement of specific combinations of activating receptors on NK cells dictates qualitatively distinct responses and can lead to synergistic effects for activation of effector cell function (9, 10).

The ability of NK cells to kill tumors in vitro has been taken as indirect evidence for their participation in tumor immune surveillance. However, more direct evidence for a role of NK cells in tumor immune surveillance is limited. In murine models, however, two groups have independently reported an increased risk of tumor development in mice lacking either the NKG2D or DNAM-1 receptor (11, 12). DNAM-1-deficient mice developed significantly more DNAM-1 ligand-expressing fibrosarcoma and papilloma tumors compared with wild-type mice in response to the chemical carcinogens methylcholanthrene and 7,12-dimethylbenz[a]anthracene (12). These results substantiate the notion of DNAM-1 playing an important role in immune surveillance of tumor development.

The DNAM-1 receptor is involved in the induction phase of both T and NK cell activation (13). Poliovirus receptor (CD155) and Nectin-2 (CD112) have been identified as ligands for DNAM-1, with CD155 appearing to have a predominant role in inducing DNAM-1-dependent responses (14). CD155 is widely expressed on normal cells and overexpressed on many tumor types (14–21). We recently demonstrated that the DNAM-1/CD155 interaction is crucial for recognition and killing of freshly isolated human ovarian carcinoma cells by resting allogeneic NK cells (15). Since the ovarian carcinoma cells constitutively express CD155 in combination with reduced levels of HLA class I molecules (15, 22, 23), autologous NK cells could theoretically target...
this tumor type. However, early studies suggest that the function of NK cells in patients with ovarian carcinoma is suppressed by an as yet unclear mechanism (24, 25).

Here, we have examined the activating receptor repertoire and function of tumor-associated NK (TANK) cells isolated from the tumor environment in patients with ovarian carcinoma. Our data reveal substantial alterations of the NK cell receptor repertoire, including significantly reduced expression of DNAM-1, 2B4, and CD16, resulting in impaired activation of NK cells and poor tumor cell targeting. Furthermore, we show that interactions with CD155-expressing target cells lead to reduction of DNAM-1 expression on NK cells. Taken together, our results provide a molecular mechanism that may contribute to impaired NK cell-mediated tumor rejection in ovarian carcinoma.

Materials and Methods

Cells

This study was approved by the institutional ethics committee (Karolinska Institutet, approval nos. 03-357 and 2007/1037-31/2). Patients with ovarian carcinoma were subjected to primary surgery or chemotherapy. Consent was obtained from the patient(s) and the study was approved by the local ethics committee. Blood was collected with informed consent. Blood from healthy donors was obtained from the Blood Centre at the Karolinska University Hospital. Lymphocytes were isolated from the peritoneal effusions and peripheral blood samples obtained with informed consent. Blood from healthy donors was obtained from the Blood Centre at the Karolinska University Hospital. Lymphocytes were enriched by density gradient centrifugation (Ficoll-Hypaque; Amersham Biosciences) as previously described (26). Cells were grown in 10% DMSO (Sigma-Aldrich) and 90% heat-inactivated FBS (Invitrogen) and stored in liquid nitrogen. NK cells used in functional experiments were isolated by positive magnetic bead selection with anti-PE kit (EasySep kit; StemCell Technologies) or isolated from peritoneal effusions using the CD45 EpCAM mAb on ice following Fc receptor blockade with IgG (1 mg/ml). Purified overnight IL-2-activated NK cells were coincubated with target cells at a ratio of 10:1 in a final volume of 200 µl for 3 h at 37°C and 5% CO2. At the end of the assay, tumor cells were stained with the anti-EpCAM mAb on ice following Fc receptor blockade with IgG (1 mg/ml) for 6 h. Experiments involving stimulation by PMA (200 µM) and ionomycin (1000 µg/ml) were stopped after 2 h of incubation.

Flow cytometry-based cytotoxicity assays

Flow cytometry

Analysis of NK cell activation

NK cells were coincubated with target cells at a ratio of 1:1 in a final volume of 200 µl in 96-well plates at 37°C and 5% CO2. After 1 h of coincubation, GolgiPlug was added. Before analysis, cells were stained with a dead cell marker and a combination of anti-CD3, anti-CD56, and anti-CD107a mAbs for 15 min on ice, followed by washing and permeabilization (BD Biosciences). Intracellular staining was performed with anti-IFN-γ and anti-TNF-α mAbs before acquisition. P815 cells used in the reverse lysis assays were preincubated with agonistic Abs at a final concentration of 2.5 µg/ml. Abs used for ADCC were present in the assay at 10 µg/ml. Experiments involving redirected lysis or ADCC were run for 6 h. Experiments involving stimulation by PMA (200 µM) and ionomycin (1000 µg/ml) were stopped after 2 h of incubation.

Flow cytometry-based cytotoxicity assays

Fresh ovarian carcinoma cells were isolated and HLA class I was blocked by the anti-HLA class I mAbs A6-136 and 12B4 at the dilution 1/1 and 1/100, respectively (both mAbs were provided by Dr. D. Pende, Genoa, Italy). Purified overnight IL-2-activated NK cells were coincubated with target cells at a ratio of 10:1 in a final volume of 200 µl for 3 h at 37°C and 5% CO2. At the end of the assay, tumor cells were stained with the anti-EpCAM mAb on ice following Fc receptor blockade with IgG (1 mg/ml) and Luminex assay. Cells were shielded from light and incubated 10 min with 7-amino-actinomycin D (BD Biosciences) at room temperature before immediate acquisition on the CyAn instrument.

Analysis of DNAM-1 expression

Healthy donor-derived PBMCs were coincubated with target cells at a ratio of 10:1 as described above. Before analysis, cells were stained with a dead cell marker and a combination of anti-CD3, anti-CD14, anti-CD56, and anti-CD107a mAbs for 15 min on ice. GolgiPlug and an anti-CD107a mAb were used for the analysis of DNAM-1 expression on activated cells as described for the CD107a assay above. The relative expression (MRFI) was calculated as the mean fluorescence intensity of DNAM-1 on NK cells coincubated with target cells divided by the mean fluorescence intensity of DNAM-1 on NK cells incubated without target cells.

Statistics

Statistical analyses were performed with GraphPad Prism (GraphPad Software) using the Wilcoxon and the Mann-Whitney t tests for paired and unpaired groups, respectively, and one-way ANOVA with Dunn’s multiple comparison for multiple comparison analyses. Correlation analysis was performed using Spearman’s correlation test.

Results

Perturbed NK cell receptor repertoires and altered subset frequencies in peritoneal effusions of patients with ovarian carcinoma

We performed a high-resolution phenotypic analysis of NK cells from peritoneal effusions and peripheral blood of patients with ovarian carcinoma. Tumor-associated NK cells differed substantially from autologous NK cells in peripheral blood and NK cells from sex- and age-matched healthy controls. First, we observed an increased proportion of CD56bright NK cells constituting on average 32% of all NK cells in the peritoneal effusions, compared with ~10% in peripheral blood (Fig. 1A and B) (28). Containing with CD16, NKG2A, KIRs, CD57, and LIRLR-B1 confirmed a classical phenotype of the CD56bright NK cells (Fig. 1A) (3). Second,
FIGURE 1. Increased proportion of CD56<sup>bright</sup> NK cells and perturbed expression of NK cell receptors on CD56<sup>dim</sup> NK cells in the tumor environment. 

A, Representative dot plot diagrams of PBLs from a healthy donor (HD; left), as well as of PBLs (middle) and autologous tumor-associated lymphocytes (TAL) in peritoneal effusion (right) from an ovarian carcinoma patient. The histograms show expression of markers used to define the two NK cell subsets.

B, Proportion of CD56<sup>bright</sup> NK cells in total NK cells in PBLs from HDs (■; n = 6), PBL (▲; n = 11) and TAL in patients (▽; n = 11).

C, Representative histograms for the expression of activating and costimulatory NK cell receptors on CD56<sup>dim</sup> NK cells in PBLs (dashed line) and peritoneal effusions (line) compared with isotype-matched control mAb (filled).

D, Expression of activating and costimulatory NK cell receptors on CD56<sup>dim</sup> NK cells in PBLs from HDs (■; n = 6), PBL (▲; n = 11) and TAL (▽; n = 11) from patients. Lines indicate mean fluorescence intensity for each receptor. * p < 0.05; **, p < 0.01; *** p < 0.001.
Tumor-associated NK cells displayed multiple alterations in the receptor repertoires of both the CD56dim and CD56bright NK cell subsets (Fig. 1, C and D, and supplemental Fig. 1, respectively). Analysis of the CD56dim NK cell subset revealed that expression of the activating receptor DNAM-1 was significantly lower on tumor-associated NK cells compared with NK cells isolated from peripheral blood of patients and healthy donors (Fig. 1D). Similarly, the coactivating receptor 2B4 (CD244) was relatively lower on tumor-associated NK cells (Fig. 1D). Furthermore, the CD16 receptor, primarily expressed on CD56dim NK cells, was significantly decreased on the tumor-associated CD56dim NK cells (Fig. 1D). In contrast, the expression of NKp46 and NKG2D was slightly higher on NK cells within the tumor environment, whereas the expression of NKp30 was unaltered compared with NK cells in peripheral blood (Fig. 1D). Analysis of the CD56bright NK cell subset revealed similar receptor alterations as for CD56dim NK cells (supplemental Fig. 1).

These results demonstrate that NK cells in the tumor environment display altered proportions of the CD56 bright and CD56 dim subsets compared with peripheral blood and perturbed expression of activating NK cell receptors, including significant down-modulation of DNAM-1, 2B4, and CD16.

Changes in 2B4 and NKG2D expression on CD56dim NK cells correlate with increased proportion of CD56bright NK cells in the peritoneal effusion

The variable degrees of receptor modification among patients prompted us to examine whether there was any correlation between the increased proportion of CD56bright NK cells and the observed down-regulation of DNAM-1, 2B4, and CD16. Interestingly, the increased relative proportion of CD56bright NK cells in the peritoneal effusion correlated to the loss of expression of the 2B4 receptor ($p < 0.05$). An opposite tendency was observed for the expression of NKG2D ($p = 0.07$), whereas no correlation was observed for none of the other receptors studied, including DNAM-1, NKp30, NKp46, and CD16 (Fig. 2). This observation indicates that the coordinated increase in CD56bright NK cells and changes in 2B4 and NKG2D are related and may depend on environmental factors. However, despite the fact that several cytokines, including IL-2, IL-10, and IFN-γ, were increased in peritoneal effusions compared with autologous plasma, exposure of peripheral blood-derived NK cells to peritoneal effusion from patients with high proportions of CD56bright NK cells did not mimic the observed changes in receptor expression (data not shown).

Importantly, neither of these observations could explain the reduced expression of the DNAM-1 receptor. Since this receptor is of fundamental importance for the recognition and killing of several human tumors, including ovarian carcinoma (15–17, 29), we next investigated the mechanism behind the modulation of DNAM-1 receptor expression in the tumor environment.

Loss of DNAM-1 expression upon interaction with CD155-expressing freshly isolated ovarian carcinoma cells

Receptor-ligand interactions have been shown to down-modulate surface expression of several NK cell receptors, including NKG2D (30, 31). Therefore, we studied if there was a correlation between the reduced levels of DNAM-1 expression on NK cells in peritoneal effusions with the expression of CD155 on autologous ovarian carcinoma cells. This analysis revealed a significant inverse correlation between the relative reduction of DNAM-1 expression on tumor-associated CD56dim NK cells and the expression of CD155 on carcinoma cells (Fig. 3A). To more directly assess the role of
CD155, we used a recently described system in which S2 insect cells are transfected with ligands of human NK cell receptors ligands (27). Coincubation of peripheral blood NK cells from healthy donors with S2 cells expressing CD155 induced specific down-modulation of DNAM-1 (Fig. 3B). Importantly, no reduction of DNAM-1 expression was observed upon interaction with S2 cells expressing the NKG2D ligand ULBP1 (Fig. 3B).

To investigate the consequences of receptor ligation in a more physiological setting, we used a panel of freshly isolated ovarian carcinoma cells and tumor cell lines, all expressing CD155 (supplemental Fig. 2). In agreement with our previous report, all tested tumor samples were negative for Nectin-2 (data not shown and Ref. 15). Coincubation of NK cells with the ovarian carcinoma cell lines CaOV-4 and Skov3 as well as the freshly isolated ovarian carcinoma cells resulted in a reduction of DNAM-1 expression (Fig. 3C). Similarly, DNAM-1 was significantly down-modulated upon coincubation with K562 cells that also express CD155. In contrast, coincubation with the NK cell-resistant P815 cell line and the NK-sensitive 721.221 cell line, both lacking CD155 expression, did not induce DNAM-1 down-modulation, regardless of the degree of NK cell activation (Fig. 3C and data not shown). Kinetic experiments demonstrated a gradual reduction of DNAM-1 expression, occurring over 12 h during coincubation with fresh tumor cells (Fig. 3D).

To assess the role of soluble factors in the modulation of DNAM-1 receptor expression, we next coincubated healthy donor-derived NK cells with target cells in the presence of a transwell membrane abrogating physical interactions between DNAM-1 and CD155. DNAM-1 expression remained intact when physical interactions were prevented, whereas reduced DNAM-1 expression was observed when target cells expressing CD155 were allowed to interact with the NK cells (Fig. 4A). Furthermore, maintaining NK cells in peritoneal effusions for 36 h did not affect surface expression of DNAM-1, excluding a role for soluble factors including DNAM-1 ligands and/or cytokines in the down-modulation of this receptor within this time frame (Fig. 4B).

Hence, these data suggests that a physical interaction between CD155 and DNAM-1 is required to induce a loss of DNAM-1 receptor expression.

Impaired activation of tumor-associated NK cells upon specific stimulation via the DNAM-1 receptor

To explore the functional responsiveness of CD56dim tumor-associated NK cells, we monitored the cell surface expression of CD107a as a surrogate marker for degranulation (32). The overall responsiveness of patient-derived CD56dim NK cells following
DNAM-1 is an activating NK cell receptor recently demonstrated to play an important role in tumor immune surveillance. Here we describe that receptor engagement attenuates DNAM-1 expression on NK cells, leading to hyporesponsiveness. These results suggest that chronic receptor-ligand interactions may cause loss of DNAM-1 expression on NK cells in the tumor environment, thereby contributing to poor NK cell-mediated elimination of ovarian carcinoma cells and possibly also other tumors expressing DNAM-1 ligands.

Discussion

DNAM-1 expression on tumor-associated NK cells has been of interest in a redirected lysis assay. In agreement with our previously published data on resting NK cells, stimulation of DNAM-1, Nkp46, 2B4, or NKG2D alone did not induce CD107a surface expression (data not shown and Ref. 10). Degranulation of tumor-associated NK cells upon costimulation by 2B4 and DNAM-1 was significantly impaired, reflecting the loss of receptor expression on tumor-associated NK cells (Figs. 1D and 5, C and D). Costimulation via the NKG2D and Nkp46 receptors, which trigger Ca\(^{2+}\) flux synergistically (10) but are consistently less efficient in triggering degranulation (our unpublished observation), was not significantly different between tumor-associated NK cells and peripheral blood NK cells, despite a slight up-regulation of these receptors on tumor-associated NK cells (Figs. 1D and 5, C and D) (10). Similar response patterns were observed for the CD56\(^{dim}\) NK cells when the production of IFN-\(\gamma\) and TNF-\(\alpha\) was assessed (supplemental Fig. 4).

Finally, we used a previously described flow cytometry-based cytotoxicity assay (15) to examine how dysregulation of NK receptors affected recognition of autologous freshly isolated ovarian carcinoma cells. To allow a direct comparison of allogeneic vs autologous NK cells and to assess the net signaling through activating receptors, the cytotoxicity experiments were performed in the presence of complete blockade of HLA class I. Tumor-associated NK cells displayed impaired killing of autologous carcinoma cells compared with both autologous and allogeneic peripheral blood-derived NK cells (Fig. 5E).

Taken together, these data demonstrate that tumor-associated NK cells were fully functional upon receptor-independent stimulation, but hypofunctional upon stimulation via specific or multiple receptors mediating natural cytotoxicity, reflecting the net sum of alterations in the receptor expression.

**Tumor-associated NK cells fail to target autologous tumor cells by ADCC due to impaired activation via the CD16 receptor**

The redirected lysis assay was used to assess the consequences of reduced CD16 expression on tumor-associated NK cells. Stimulation of CD16 on CD56\(^{dim}\) NK cells from peripheral blood led to significantly lower degranulation and cytokine production compared with triggering of CD16 on the corresponding subset in peripheral blood (Fig. 6, A and B, and data not shown). Next, NK cell-mediated ADCC was evaluated against tumor cells coated with trastuzumab (Herceptin), a mAb specific for human epidermal growth factor receptor 2 (HER-2/neu) that is expressed by metastatic ovarian carcinoma cells (33). The response of tumor-associated NK cells upon ADCC to Ab-coated autologous ovarian carcinoma cells was abrogated compared with NK cells isolated from peripheral blood from the same patients (Fig. 6C). Rituximab, another humanized mAb used in clinical therapy targeting CD20-expressing cells, was used as a negative control Ab and resulted in low responses by both NK cell populations. Thus, tumor-associated NK cells display an impaired activation when stimulated via the CD16 receptor pathway, leading to an abrogated capacity for ADCC against autologous ovarian carcinoma cells.

### Discussion

DNAM-1 expression on tumor-associated NK cells has been of interest in a redirected lysis assay. In agreement with our previously published data on resting NK cells, stimulation of DNAM-1, Nkp46, 2B4, or NKG2D alone did not induce CD107a surface expression (data not shown and Ref. 10). Degranulation of tumor-associated NK cells upon costimulation by 2B4 and DNAM-1 was significantly impaired, reflecting the loss of receptor expression on tumor-associated NK cells (Figs. 1D and 5, C and D). Costimulation via the NKG2D and Nkp46 receptors, which trigger Ca\(^{2+}\) flux synergistically (10) but are consistently less efficient in triggering degranulation (our unpublished observation), was not significantly different between tumor-associated NK cells and peripheral blood NK cells, despite a slight up-regulation of these receptors on tumor-associated NK cells (Figs. 1D and 5, C and D) (10). Similar response patterns were observed for the CD56\(^{dim}\) NK cells when the production of IFN-\(\gamma\) and TNF-\(\alpha\) was assessed (supplemental Fig. 4).

Finally, we used a previously described flow cytometry-based cytotoxicity assay (15) to examine how dysregulation of NK receptors affected recognition of autologous freshly isolated ovarian carcinoma cells. To allow a direct comparison of allogeneic vs autologous NK cells and to assess the net signaling through activating receptors, the cytotoxicity experiments were performed in the presence of complete blockade of HLA class I. Tumor-associated NK cells displayed impaired killing of autologous carcinoma cells compared with both autologous and allogeneic peripheral blood-derived NK cells (Fig. 5E).

Taken together, these data demonstrate that tumor-associated NK cells were fully functional upon receptor-independent stimulation, but hypofunctional upon stimulation via specific or multiple receptors mediating natural cytotoxicity, reflecting the net sum of alterations in the receptor expression.

**Tumor-associated NK cells fail to target autologous tumor cells by ADCC due to impaired activation via the CD16 receptor**

The redirected lysis assay was used to assess the consequences of reduced CD16 expression on tumor-associated NK cells. Stimulation of CD16 on CD56\(^{dim}\) NK cells from peripheral blood led to significantly lower degranulation and cytokine production compared with triggering of CD16 on the corresponding subset in peripheral blood (Fig. 6, A and B, and data not shown). Next, NK cell-mediated ADCC was evaluated against tumor cells coated with trastuzumab (Herceptin), a mAb specific for human epidermal growth factor receptor 2 (HER-2/neu) that is expressed by metastatic ovarian carcinoma cells (33). The response of tumor-associated NK cells upon ADCC to Ab-coated autologous ovarian carcinoma cells was abrogated compared with NK cells isolated from peripheral blood from the same patients (Fig. 6C). Rituximab, another humanized mAb used in clinical therapy targeting CD20-expressing cells, was used as a negative control Ab and resulted in low responses by both NK cell populations. Thus, tumor-associated NK cells display an impaired activation when stimulated via the CD16 receptor pathway, leading to an abrogated capacity for ADCC against autologous ovarian carcinoma cells.
DNAM-1-dependent rejection of tumors was provided by increased formation of ligand-expressing fibrosarcomas and papillomas after treatment of mice with the carcinogens methylcholanthrene and 7,12-dimethylbenz[a]anthracene, respectively (12). These studies provide the first direct evidence for a central role for DNAM-1 in tumor immune surveillance.

DNAM-1 is important for NK cell-mediated recognition of several human tumors, including neuroblastoma, myeloma, and Ewing sarcoma (16, 17, 29, 35). We have previously shown that the DNAM-1/CD155 interaction is crucial for the recognition of freshly isolated ovarian carcinoma by allogeneic NK cells (15). Thus, loss of DNAM-1 expression on NK cells may explain the inability of patient-derived NK cells to kill autologous tumors (24).

Suppression of NK cell function in cancer patients has been associated with reduced expression of activating NK cell receptors, but the mechanisms for receptor modulations are not fully understood (36–38). Mechanisms such as shedding of ligands, chronic ligand exposure, and trogocytosis have been described (30, 31, 39, 40). Interestingly, CD96, a NK cell receptor that like DNAM-1 binds CD155, was shown to be down-regulated upon ligand engagement (41). Since ovarian carcinoma cells constitutively express CD155 (15), we speculated that similar mechanisms could be responsible for the down-modulation of DNAM-1 on tumor-associated NK cells. Indeed, we were able to demonstrate that peripheral blood NK cells lost DNAM-1 expression within hours of exposure to CD155-expressing targets. Down-modulation of
DNAM-1 was dependent on physical contact with target cells expressing CD155 since no change in DNAM-1 expression was observed when effectors and targets were separated in transwell experiments or when NK cells were exposed to peritoneal effusions. Interestingly, we found an inverse correlation between the expression of CD155 on ovarian carcinoma cells and the expression of DNAM-1 on autologous tumor-associated NK cells, supporting the notion that these events take place in vivo.

Receptor-ligand interactions occurring during target recognition could not explain the loss of 2B4 expression since the ligand for 2B4, CD48, is not expressed by ovarian carcinoma cells. Furthermore, these mechanisms have not been shown to have a central role in ovarian carcinoma (28). Preferential proliferation of CD56bright cells and in modulating expression of 2B4, NKG2D, and NKp46, it does not seem to play a role for the observed loss of DNAM-1. Indeed, culturing NK cells in the presence of patient-derived peritoneal effusions had no effect on down-modulating the expression of CD16 on NK cells from ovarian carcinoma patients, although the role in regulating DNAM-1 expression was not investigated (28, 52). Furthermore, several reports have noted that cytokines can modulate the expression of natural cytotoxicity receptors and NKG2D (38, 53, 54). IL-2 and TNF-α have been shown to increase the expression of DNAM-1 in T cells, whereas TGF-β can counteract this effect (55). A recent publication also demonstrated a MIF-mediated transcriptional down-regulation of NKG2D in ovarian carcinoma (37).

There is abundant evidence for a role of soluble factors as mediators of NK cell receptor regulation. MUC-16 (CA125), known to inhibit the cytotoxicity of NK cells, was recently shown to down-modulate the expression of CD16 on NK cells from ovarian carcinoma patients, although the role in regulating DNAM-1 expression was not investigated (28, 52).

Increasing knowledge of the molecular specificities in NK cell-mediated tumor recognition provides new possibilities for developing more effective immunotherapeutic interventions (56). For efficient tumor rejection, strategies to circumvent the immunomodulatory effects of tumor environments are likely needed in combination with adoptive transfer of NK cells. A concern raised by the present study is that sequential killing of multiple target cells (57) may be hampered through the loss of DNAM-1 expression following initial target cell contact. Repetitive adoptive transfer of DNAM-1-expressing NK cells may help to overcome the continuous down-regulation of DNAM-1 upon interaction with CD155-expressing tumor targets. Chimeric NKG2D receptors
have been shown to enhance tumor targeting by CTLs (58). Similar approaches based on effector cells that stably express chimeric DNAM-1 receptors could theoretically also enable effective tumor rejection by NK cells.

The efficacy of mAbs for the treatment of malignancies such as lymphoma and breast cancer is well established (59). Since metastatic ovarian carcinoma cells uniformly express the tumor Ag Her2/neu, they could serve as targets for the humanized mAb trastuzumab (33). Apart from changes in CD16-expression, which severely impaired tumor-associated NK cell ADCC toward trastuzumab-coated fresh ovarian carcinoma cells. In contrast, autologous peripheral blood NK cells displayed robust activation upon coincubation with trastuzumab-coated targets. It has previously been reported that the loss of the signal transducing molecules FcεRIy and CD3-ζ in tumor-associated lymphocytes of patients with ovarian carcinoma led to reduced expression of CD16 and depressed the proliferative response to CD16 stimulation (60). Moreover, monocye-dervied macrophages from both peripheral blood and peritoneal effusions of ovarian cancer patients had less ADCC activity than did the corresponding cells from normal donors (61). These results indicate that targeting of metastatic ovarian carcinoma with mAbs, via NK cell-mediated ADCC, may be less effective than anticipated.

In conclusion, we have demonstrated that the loss of DNAM-1 expression on tumor-associated NK cells results in impaired NK cell activation and that loss of CD16 abrogates the killing of trastuzumab-coated autologous ovarian carcinoma cells. Moreover, we provide evidence for the contribution of CDNAM-1/CD155 interactions to the reduction of DNAM-1 expression, suggesting that chronic receptor-ligand interactions in the tumor environment may induce loss of DNAM-1 on tumor-associated NK cells. These results may have implications for the design of future protocols of adoptive NK cell- and Ab-based immunotherapies for ovarian carcinoma and possibly other human tumors.

Disclosures

The authors have no financial interests of conflict.

References

1. Karre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675–678.
2. Cooper, M. A., T. A. Fehniger, and M. A. Caligiuri. 2001. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood 97: 3111–3117.
3. Jacobs, R., G. Hintzen, A. Kemper, K. Beul, S. Kempf, G. Behrens, K. W. Sykora, and R. B. Herberman. 1987. Inhibition of clonogenic virus receptor interaction. Cancer Res. 47: 2051–2057.
4. Lotzova, E., C. A. Savary, and R. B. Herberman. 1987. Inhibition of clonogenic growth of fresh leukaemia cells by unstimulated and IL-2-stimulated NK cells of normal donors. Leukemia Res. 11: 1059–1066.
5. Shibuya, A., D. Campbell, C. Hannum, H. Yssel, K. Franz-Bacon, S. Honda, T. Yasui, H. Kikutani, K. Shibuya, and A. Shibuya. 2008. Accelerated telomere lengthening in tumor-associated lymphocytes of patients with ovarian carcinoma. J. Exp. Med. 207: 1159–1172.
6. Iguchi-Manaka, A., H. Kai, Y. Yamashita, K. Shibita, S. Tahara-Hanaoka, S. Honda, T. Yasui, H. Kikutani, K. Shibuya, and A. Shibuya. 2008. Activated natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. J. Immunol. 180: 6491–6498.
7. Lotzova, E., C. A. Savary, and R. B. Herberman. 1987. Inhibition of clonogenic growth of fresh leukaemia cells by unstimulated and IL-2-stimulated NK cells of normal donors. Leukemia Res. 11: 1059–1066.
8. Shibuya, A., D. Campbell, C. Hannum, H. Yssel, K. Franz-Bacon, S. Honda, T. Yasui, H. Kikutani, K. Shibuya, and A. Shibuya. 2008. Accelerated telomere lengthening in tumor-associated lymphocytes of patients with ovarian carcinoma. J. Exp. Med. 207: 1159–1172.
9. Shibuya, A., D. Campbell, C. Hannum, H. Yssel, K. Franz-Bacon, T. McElhaney, T. Kitamura, J. Nicholl, G. R. Sutherland, L. L. Lanier, and J. H. Phillips. 1996. DNAM-1, a novel adhesion molecule involved in the cytolytic function of T lymphocytes. Immunity 4: 573–581.
10. Bottino, C., R. Castriconi, D. Pende, P. Rivera, M. Nanni, B. Carmellola, C. Cantoni, J. Grasso, S. Marconcino, N. Reynouard, R. M. et al. 2003. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human natural killer cell (CD122) activating molecule. J. Exp. Med. 198: 557–567.
11. Carlsten, M., N. K. Bjorkstrom, H. Norell, Y. Bryceson, T. van Hall, B. L. Schumann, M. Hansen, K. Schueller, S. Kiessling, H. G. Ljunggren, and K. J. Malmberg. 2007. DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer Res. 67: 1317–1325.
12. Shibuya, A., R. Dondero, M. V. Corrias, E. Lanino, D. Pende, L. Moretta, C. Bottino, and A. Moretta. 2004. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res. 64: 9180–9184.
13. El-Sherby, Y. M., J. L. Meade, T. D. Holmes, D. McGonagle, S. L. Mackie, A. W. Morgan, G. Cook, S. Feyer, S. J. Richards, F. E. Davies, et al. 2007. The requirement for DNAM-1, NKGD2, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 67: 8444–8449.
14. Karre, K., H. G. Ljunggren, G. Piontek, and R. Kiessling. 1986. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675–678.
15. Shibuya, A., D. Campbell, C. Hannum, H. Yssel, K. Franz-Bacon, S. Honda, T. Yasui, H. Kikutani, K. Shibuya, and A. Shibuya. 2008. Accelerated telomere lengthening in tumor-associated lymphocytes of patients with ovarian carcinoma. J. Exp. Med. 207: 1159–1172.
16. Shibuya, A., D. Campbell, C. Hannum, H. Yssel, K. Franz-Bacon, S. Honda, T. Yasui, H. Kikutani, K. Shibuya, and A. Shibuya. 2008. Accelerated telomere lengthening in tumor-associated lymphocytes of patients with ovarian carcinoma. J. Exp. Med. 207: 1159–1172.
35. Carlsten, M., K. J. Malmberg, and H. G. Ljunggren. 2009. Natural killer cell-mediated lysis of freshly isolated human tumor cells. Int. J. Cancer 124: 757–762.
36. Costello, R. T., S. Sivori, E. Marcellino, M. Lafage-Pochitaloff, M. J. Mozzicaccia, D. Reviron, J. A. Gastaut, D. Dehde, D. Olive, and A. Moretta. 2002. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99: 3661–3667.
37. Krockenberger, M., Y. Dombrowski, C. Weidler, M. Ossadnik, A. Honig, S. Hausler, H. Voigt, J. C. Becker, L. Leng, A. Steine, et al. 2008. Macrophage migration inhibitory factor contributes to the immune escape of ovarian cancer by down-regulating NK2D2. J. Immunol. 180: 7338–7348.
38. Lee, J. C., K. M. Lee, D. W. Kim, and D. S. Heo. 2004. Elevated TGF-β1 secretion and down-modulation of NK2D2 underlines impaired NK cytotoxicity in cancer patients. J. Immunol. 172: 7335–7340.
39. Ogasawara, K., J. A. Hamerman, H. Hsin, S. Chikuma, H. Bour-Jordan, T. Chen, T. Pertel, C. Carnaud, J. A. Bluestone, and L. L. Lanier. 2003. Impairment of NK cell function by NK2D2 modulation in NOD mice. Immunity 18: 41–51.
40. Oppenheim, D. E., S. J. Roberts, S. L. Clarke, R. Filler, J. M. Lewis, R. E. Tigelala, M. Girardi, and A. C. Hayward. 2005. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 6: 928–937.
41. Fuchs, A., M. Cella, E. Giurisato, A. S. Shaw, and M. Colonna. 2004. Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155). J. Immunol. 172: 3994–3998.
42. Dunn, C., M. Brunetto, G. Reynolds, T. Christophides, P. T. Kennedy, P. Lampertico, A. Das, A. R. Lopes, P. Borrow, K. Williams, et al. 2007. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J. Exp. Med. 204: 667–680.
43. Eidukaite, A., A. Staurys, and V. Tamosiunas. 2004. Differential expression of KIRs, NKG2D, and CD96 molecules on decidual and peripheral blood CD56bright and CD56dim natural killer cell subsets. Fertil. Steril. 81(Suppl. 1): 863–868.
44. Feiniger, T. A., M. A. Cooper, G. J. Nuovo, M. Cella, F. Facchetti, M. Colonna, and M. A. Caligiuri. 2003. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 101: 3052–3057.
45. King, A., P. P. Jokhi, T. D. Burrows, L. Gardner, A. M. Sharkey, and Y. W. Loke. 2001. Functions of human decidual NK cells. Am. J. Reprod. Immunol. 35: 258–260.
46. Bauerhofer, T., I. Kuss, B. Henderson, A. S. Baum, and T. L. Whiteside. 2003. Preferential apoptosis of CD56bright natural killer cell subset in patients with cancer. Eur. J. Immunol. 33: 119–124.
47. Drake, P. M., M. D. Gunn, L. F. Charo, C. L. Tsou, Y. Zhou, L. Huang, and S. J. Fisher. 2001. Human placental cytotrophoblasts attract monocytes and CD56bright natural killer cells via the actions of monocyte inflammatory protein 1a. J. Exp. Med. 193: 1199–1212.
48. Harlin, H., M. Hanson, C. C. Johansson, D. Sakurai, I. Poschke, H. Norell, K. J. Malmberg, and R. Kiessling. 2007. The CD16+ CD56bright NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56dim subset. J. Immunol. 179: 4513–4519.
49. Caligiuri, M. A., A. Zmuidzinas, T. J. Manley, H. Levine, K. A. Smith, and J. Ritz. 1990. Functional consequences of interleukin 2 receptor expression on resting human lymphocytes: identification of a novel natural killer cell subset with high affinity receptors. J. Exp. Med. 171: 1509–1526.
50. Nishikawa, K., S. Saito, T. Morii, Y. Kato, N. Narita, M. Ichijo, Y. Ohashi, T. Takeshita, and K. Sugamura. 1990. Differential expression of the interleukin 2 receptor β (p75) chain on human peripheral blood natural killer subsets. Int. Immunol. 2: 481–486.
51. Vosshenrich, C. A., M. E. Garcia-Ojeda, S. I. Samson-Villegge, V. Pasqualetto, L. Einaui, O. Richard-Le Goff, E. Corcuff, D. Guy-Grand, B. Rocha, A. Cumano, et al. 2006. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat. Immunol. 7: 1217–1224.
52. Patankar, M. S., Y. Jing, J. C. Morrison, J. A. Belisle, F. A. Lattanzio, Y. Deng, N. K. Wong, H. R. Morris, A. Dell, and G. F. Clark. 2005. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol. Oncol. 99: 704–713.
53. Sutherland, C. L., B. Rabinovich, N. J. Chalupny, P. Brawand, R. Miller, and D. Cosman. 2006. ULBP3, human ligands of the NK2D2 receptor, stimulate tumor immunity with enhancement by IL-15. Blood 108: 1313–1319.
54. Vitale, M., C. Bottino, S. Sivori, L. Sanservino, R. Caustronci, E. Marcellino, R. Augugliaro, L. Moretta, and A. Moretta. 1998. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells, is involved in non-major histocompatibility complex-restricted tumor cell lysis. J. Exp. Med. 187: 2065–2072.
55. Jin, B., J. L. Scott, M. A. Vadas, and G. F. Burns. 1989. TGFβ1 down-regulates TL1A1 expression and inhibits the differentiation of precursor lymphocytes into CTL and LAK cells. Immunity 66: 570–576.
56. Ljunggren, H. G., and K. J. Malmberg. 2007. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7: 329–339.
57. Bhat, R., and C. Watzl. 2007. Serial killing of tumor cells by human natural killer cells: enhancement by therapeutic antibodies. PLoS ONE 2: e326.
58. Barber, A., T. Zhang, L. R. DeMars, J. Conejo-Garcia, K. F. Roby, and C. L. Sentman. 2007. Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer. Cancer Res. 67: 5003–5008.
59. Boyiadzis, M., and K. A. Foon. 2008. Approved monoclonal antibodies for cancer therapy. Expert Opin. Biol. Ther. 8: 1151–1158.
60. Lai, P., H. Rabinovich, P. A. Crowley-NoWick, M. C. Bell, G. Mantovani, and T. L. Whiteside. 1996. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin. Cancer Res. 2: 161–173.
61. Gordon, I. O., and R. S. Freedman. 2006. Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin. Cancer Res. 12: 1515–1524.